This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Cohen, Ezra
| Item Type | Name |
|
Concept
|
Thyroid Neoplasms
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Thyroid cancer: burden of illness and management of disease.
|
|
Academic Article
|
Cabozantinib for the treatment of advanced medullary thyroid cancer.
|
|
Academic Article
|
New approaches to thyroid cancer.
|
|
Academic Article
|
Novel molecular targeted therapies for refractory thyroid cancer.
|
|
Academic Article
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
|
Academic Article
|
A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.
|
|
Academic Article
|
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
|
|
Academic Article
|
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
|
|
Academic Article
|
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
|
|
Academic Article
|
Cabozantinib in progressive medullary thyroid cancer.
|
|
Academic Article
|
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
|
|
Academic Article
|
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
|
|
Academic Article
|
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
|
|
Academic Article
|
Phase 2 study of sunitinib in refractory thyroid cancer.
|
|
Academic Article
|
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
|
|
Academic Article
|
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
|
|
Academic Article
|
An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
|